THE US Food and Drug
Administration (FDA) has said it
will investigate issues around the
industry’s abbreviated new drug
applications (ANDAs).
Congress is pushing the FDA to
fast-track generic approvals where
original brands are ramping up
prices, but the FDA has rejected
more than twice as many ANDAs
as it approved over the last four
months.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Feb 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.